Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
975 DKK | -2.99% | -7.11% | -26.69% |
Mar. 27 | Orphazyme A/S Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 04 | FDA Extends Review of Zevra's Arimoclomol by Three Months | DJ |
Sales 2022 | - | Sales 2023 | - | Capitalization | 46.96M 329M |
---|---|---|---|---|---|
Net income 2022 | 26M 182M | Net income 2023 | -26M -182M | EV / Sales 2022 | - |
Net cash position 2022 | 42.46M 297M | Net cash position 2023 | 18.21M 127M | EV / Sales 2023 | - |
P/E ratio 2022 |
1.19
x | P/E ratio 2023 |
-1.8
x | Employees | 1 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 59.56% |
1 day | -2.99% | ||
1 week | -7.11% | ||
Current month | -18.74% | ||
1 month | -18.03% | ||
3 months | -22.26% | ||
6 months | +9.55% | ||
Current year | -26.69% |
Managers | Title | Age | Since |
---|---|---|---|
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Jakob Have
BRD | Director/Board Member | 43 | 23-05-16 |
Chairman | 53 | 23-05-16 | |
Jakob Bendtsen
CEO | Chief Executive Officer | 46 | 23-05-16 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 975 | -2.99% | 62 |
24-04-22 | 1,005 | -4.01% | 29 |
24-04-19 | 1,047 | -4.80% | 66 |
24-04-18 | 1,100 | +4.74% | 7 |
24-04-17 | 1,050 | +0.04% | 3 |
Delayed Quote Nasdaq Copenhagen, April 23, 2024 at 06:45 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-26.69% | 5.06M | |
+2.49% | 96.73B | |
-0.32% | 21.31B | |
-16.61% | 21.21B | |
-5.20% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- ORPHA Stock